Delivery Order SPE2DB22D2206-SPE2DB24FJG68

Award Date 7/18/24
Potential Completion Date 8/8/24
Potential Value $38K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The order is for 240mg/24ml vials of the drug OPDIVO, with a potential value of $38,237.00 and a performance period through February 22, 2024. This order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of...
This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Opdivo, a specialty cancer medication. The contract is a firm-fixed-price delivery order with a ceiling value of $9,937.86 and a period of performance through May 29, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $31,311.18 firm-fixed-price contract is for the supply of Opdivo, a 240 mg/24 mL cancer medication, with a period of performance through May 2025. The contract is not set aside and represents an order under AmerisourceBergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. This IDC serves as a comprehensive...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, with a ceiling value of $15,294.80. The order is for 4,565,628,285 units of OPDIVO 240 MG/24 ML VIAL 24ML, a specialty medication. The order has an ultimate completion date of September 20, 2024 and was awarded on August 29, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,968.93, is for the delivery of Opdivo 240 mg/24 ml vials, a medication used to treat various types of cancer. The contract is not set aside and is a firm fixed-price delivery order with a performance period through May 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of 240 mg/24 mL vials of the prescription drug Opdivo. The delivery order has a firm fixed price of $7,647.40 and a period of performance through October 31, 2024. AmerisourceBergen, a major pharmaceutical distributor, has an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999 through December 2025 for providing a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OPDIVO 240 MG/24 ML VIAL 24ML, a pharmaceutical product, with a ceiling value of $61,029.25. The contract is a firm fixed-price, non-set-aside delivery order with a period of performance through May 27, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract...
This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OPDIVO 100 MG/10 ML VIAL 10ML. The firm fixed-price contract has a ceiling value of $9,974.55 and runs through December 12, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which serves as the primary vehicle for providing a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Opdivo, a cancer medication, valued at $50,073.54. The contract has an ultimate completion date of July 28, 2025 and is not set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $39,751.44, is for the delivery of OPDIVO 240 MG/24 ML VIAL 24ML, a prescription medication. The contract is a firm fixed-price, non-set-aside delivery order with a completion date of July 21, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FJG68
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for $38,237.00. The order is for the supply of 240 mg/24 mL vials of the cancer medication OPDIVO. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation, and the ultimate completion date is August 8, 2024.

Generated 10/17/24, 9:04 AM